Back to search

Article

Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes

2023-07-13

Abstract excerpt

<h4>Summary</h4> Teplizumab has been approved for the delay of the onset of type 1 diabetes and may modulate new onset disease. We found that patients who were EBV positive at baseline had a more robust response to drug in two clinical trials and therefore postulated that latent virus has general effects in modifying immune responses. We compared the phenotypes, transcriptomes, and development of peripheral blood...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4ef2f106-58c4-5259-bfcf-eaa1fb346b77
DOI
10.1101/2023.07.11.23292344
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 DiabetesDOI 10.1101/2023.07.11.23292344
Select a neighboring publication to make it the new centre.